Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04 (Nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer and non-small cell lung cancer, as well as Phase Ib/II for the treatment of triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; Allucent for the clinical study of CAN04; and Pancreatic Cancer Action Network, as well as GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.